Imaging and Uptake Mechanism of131I-Metaiodobenzylguanidine in Medullary Thyroid Carcinoma

8Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

131I-metaiodobenzylguanidine (131I-MIBG) was also taken up by medullary thyroid carcinoma (MTC) as well as by pheochromocytoma in two patients with Sipple's syndrome. However, the mechanism of 131I-MIBG uptake by MTC has not been clarified yet. We measured tissue catecholamine levels in three MTC, since MTC can produce several active substances. Catecholamines were detected in various amounts in all MTC, but not in normal thyroid tissues. These finding suggest that MTC can produce catecholamines and therefore, 1311-MIBG is taken up and stored in catecholamine vesicles of MTC, like pheochromocytoma and neuroblastoma. We conclude that 131I-MIBG may be applied not only to diagnosis but also for the treatment of patients with MTC. © 1986, The Japan Endocrine Society. All rights reserved.

Cite

CITATION STYLE

APA

Ishi, S., Sasaki, M., Sato, T., Hirota, Y., & Kahashi, M. (1986). Imaging and Uptake Mechanism of131I-Metaiodobenzylguanidine in Medullary Thyroid Carcinoma. Endocrinologia Japonica, 33(3), 309–315. https://doi.org/10.1507/endocrj1954.33.309

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free